Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.

Journal of thrombosis and haemostasis : JTH - 1 Oct 2015

Yada K, Nogami K, Takeyama M, Ogiwara K, Wakabayashi H, Shima M

Abstract excerpt

BACKGROUND: In mild hemophilia A (MHA) patients, the risk of inhibitor development is generally low, but some factor VIII (FVIII) gene missense mutations are associated with a higher inhibitor incidence. OBJECTIVE: To investigate the mechanism(s) of inhibitor development in MHA. METHODS AND RESULTS: A patient, HA78, with MHA with a novel P1809L missense mutation in the A3 domain, exhibited significant residual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Specificity
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Blood Coagulation Tests

Share to Complement C2

Share to Cross Reactions

Share to Epitope Mapping

Share to Factor VIII

Share to Hemophilia A

Source

Identifiers

PMID: 26278069
DOI: 10.1111/jth.13118

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.PMID 26278069Read ↗

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Semantic proximity Read ↗

Mild hemophilia A.Semantic proximity Read ↗

Development of inhibitors in hemophilia A: An illustrated reviewSemantic proximity Read ↗

The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.Semantic proximity Read ↗

HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.Semantic proximity Read ↗

Coagulation factor VIII: biological basis of emerging hemophilia A therapiesSemantic proximity Read ↗

FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.Semantic proximity Read ↗

The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position.Semantic proximity Read ↗

Prothrombotic PROC variant rebalancing hemostasis in severe hemophilia A with attenuated bleeding risk.Semantic proximity Read ↗

Characteristics of inhibitors in mild/moderate haemophilia A.Semantic proximity Read ↗

Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.Semantic proximity Read ↗

Inhibitors in mild/moderate haemophilia A: an update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.